Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFOXIRI for Borderline Resectable Cholangiocarcinoma
NCT03603834Phase 2Unknown
- Sponsor
- Khon Kaen University
- Start
- Sep 2018
- Primary completion
- Aug 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in cholangiocarcinoma (CCA), sponsored by Khon Kaen University. Primary endpoint: Overall Response Rate at 15 weeks. Status: unknown.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03603834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603834.